Niraparib in combination with abiraterone acetate (Akeega®). HTA ID: 23032

Assessment Status Rapid Review Complete
HTA ID 23032
Drug Niraparib in combination with abiraterone acetate
Brand Akeega®
Indication Niraparib in combination with abiraterone acetate and prednisone/prednisolone is indicated for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.
Assessment Process
Rapid review commissioned 06/06/2023
Rapid review completed 11/07/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that niraparib in combination with abiraterone acetate not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.